Research Supported By Cystinosis UK (Summary) – Nov 2006

John Terry, Cystinosis Foundation UK


Since 2002 the Foundation has been supporting research in the Pharmacy School at Sunderland University led by Dr Roz Anderson and Prof. Paul Groundwater which is aimed at developing Prodrugs of cysteamine. Cysteamine is the active ingredient in Cystagon, the drug that all cystinotics take.

What are Prodrugs?

They are inactive forms of a known drug created by combining the drug with other chemicals that protect it from breakdown until it reaches the sites in the body where it is needed. The really clever part is to get it to breakdown to release the active drug when it gets there.

Why do we need a Prodrug of cysteamine?

Unfortunately, as delivered in Cystagon, a high proportion of the drug dose never gets to the cells where it is needed. It is broken down in the liver and is excreted in urine. It also continues to be broken down in the blood, so after 6 to 8 hours it is no longer effective. These are the reasons that a large dose has to be taken so frequently. Since it tastes unpleasant and leads to unpleasant side effects – breath and body odour, nausea and even stomach ulcers – a high, frequent dose is no fun for the patients. The aim of the work is to create taste and odour free compounds carrying the cysteamine into the cells where they are needed.

What form has our support taken?

We have been supporting a Ph.D. student, Pratap Suryadevara, who has been doing the work.

What stage is the work at?

Prodrug candidates have been synthesized and have gone through initial screening. They are being evaluated for their ability to enter kidney cells and to release the cysteamine there. The first candidate has demonstrated that ability.

What next?

Collaborations have been put in place with other researchers to quantify the reductions in taste and smell. Next, in collaboration with Dr William Van’t Hoff at Great Ormond Street, all of the candidates will be evaluated in human kidney and skin cells with the successful ones going on to be tested on human cystinotic cells. The best candidates will have their cystine depleting ability quantified in collaboration with Dr Neil Dalton at Guy’s Hospital.

Comments are closed.

QUALIFY-US Study Participants are needed for the testing of a newly developed questionnaire to measure the [...] Read more...
CNE International Conference 2024 Cystinosis Network Europe and Cystinosis Foundation UK are delighted to announce the 2024 [...] Read more...
Cystinosis Comic Book Series by Artist Kevin McCalla The Cystinosis Research Network in the US has teamed up with Kevin McCalla, a young artist who [...] Read more...
Summer 2023 Newsletter The Summer 2023 edition of our email newsletter is available to view at the link below. CFUK [...] Read more...
All website content copyright Cystinosis Foundation UK (Charity No.1074885) 1997-2013, except where explicitly stated.
Data Protection Act Registration Number: Z9880997. Please refer to our terms and conditions and our privacy policy.